Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,863 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 46,863 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.51 | $77.81 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 27 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,138 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 21, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.59 | $80.29 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 26 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,107 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 20, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.54 | $78.74 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 25 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,076 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 19, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.56 | $79.36 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 24 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,045 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 16, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.49 | $84.66 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 23 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,014 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 15, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.47 | $83.98 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 22 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,980 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 14, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.51 | $85.34 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 21 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,946 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 13, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.45 | $83.30 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 20 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,912 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 12, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.46 | $83.64 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 19 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,878 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 09, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 29 | $2.21 | $64.09 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 18 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,844 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 08, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.22 | $75.48 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 17 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,815 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 07, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.24 | $76.16 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 16 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,781 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 06, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.15 | $73.10 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 15 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,747 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 02, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.42 | $82.28 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 14 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,713 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 01, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.39 | $81.26 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 13 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,679 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 31, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.36 | $80.24 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 12 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,645 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 30, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.38 | $80.92 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,611 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 29, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.44 | $82.96 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,577 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 26, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.55 | $81.60 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,543 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 25, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.62 | $83.84 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 8 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,511 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 24, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.59 | $82.88 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 7 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,479 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 23, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.59 | $82.88 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 6 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,447 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 22, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.51 | $80.32 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 5 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,415 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 19, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.35 | $75.20 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 4 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,383 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 18, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.23 | $71.36 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 3 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,351 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 17, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.31 | $73.92 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 2 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,319 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 16, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.35 | $75.20 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,287 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 15, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 32 | $2.45 | $78.40 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 28 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,255 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 12, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.52 | $100.80 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 27 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,223 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 11, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.46 | $98.40 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 26 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,183 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 10, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.19 | $87.60 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 25 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,143 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 09, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.19 | $87.60 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 24 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,103 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 08, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.19 | $87.60 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 23 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,063 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 05, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.12 | $78.44 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 22 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,023 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 04, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.17 | $80.29 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 21 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,986 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 03, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 20 | $2.45 | $49.00 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 20 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,949 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 01, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.34 | $86.58 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 19 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,929 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 29, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.28 | $84.36 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 18 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,892 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 28, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.28 | $84.36 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 17 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,855 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 27, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.36 | $70.80 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 16 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,818 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 26, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.47 | $91.39 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 15 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,788 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 25, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.48 | $91.76 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 14 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,751 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 22, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.53 | $93.61 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 13 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,714 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 21, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.54 | $93.98 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 12 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,677 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 20, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.52 | $93.24 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,640 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 19, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.47 | $91.39 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,603 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 18, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.41 | $89.17 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,566 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 15, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.23 | $95.89 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 8 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,529 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 14, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.28 | $98.04 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 7 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,486 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 12, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.25 | $96.75 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 6 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,443 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.